Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AXYS Pharmaceuticals Inc. -- Ignore unavailable to you. Want to Upgrade?

To: bob zagorin who wrote (249)	3/8/1999 5:23:00 PM
From: bob zagorin	Read Replies (1) \| Respond to of 455

RESEARCH ALERT-Vector upgrades Axys Pharmaceutical CHICAGO, March 8 (Reuters) - Vector Securities International said Monday it upgraded Axys Pharmaceuticals Inc. <AXPH.O> to attractive from neutral, with a 12-month share price target of $8 to $10. Vector says in a report it expects progress in clinical programs this year to restore investor confidence in Axys's drug pipeline. Says the company's sustainable business model "has significant appeal in environment where access to capital is restricted." Says recent share price weakness could provide chance for "significant" near term price gains. Axys shares off 1/16 at 4-1/16 in morning activity. 10:51 03-08-99